10617 studies found for:    NCI
Show Display Options
Download search resultsDownload the search results for:
NCI (10617 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: recombinant fowlpox-prostate specific antigen vaccine;   Biological: recombinant vaccinia prostate-specific antigen vaccine;   Biological: recombinant vaccinia-B7.1 vaccine;   Biological: sargramostim;   Drug: docetaxel
2 Active, not recruiting Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Condition: Neuroendocrine Carcinoma
Interventions: Biological: Recombinant Interferon Alfa-2b;   Drug: Octreotide Acetate;   Biological: Bevacizumab
3 Completed
Has Results
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus
Conditions: Barrett Esophagus;   Esophageal Cancer
Interventions: Drug: metformin hydrochloride;   Other: placebo
4 Active, not recruiting
Has Results
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Adult Anaplastic Oligodendroglioma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Unknown  Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Biological: cetuximab;   Other: placebo;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
6 Terminated
Has Results
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: Akt inhibitor MK2206;   Drug: selumetinib;   Other: laboratory biomarker analysis
7 Completed Caspofungin Acetate in Treating Children With Fever and Neutropenia
Conditions: Fever, Sweats, and Hot Flashes;   Infection;   Kidney Cancer;   Leukemia;   Lymphoma;   Neuroblastoma;   Neutropenia;   Sarcoma
Intervention: Drug: caspofungin acetate
8 Completed Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Splenic Marginal Zone Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: alvocidib;   Drug: fludarabine phosphate;   Biological: rituximab;   Other: pharmacological study
9 Terminated FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis
10 Completed
Has Results
Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
Conditions: Precancerous Condition;   Stage I Non-small Cell Lung Cancer;   Tobacco Use Disorder
Interventions: Drug: sulindac;   Other: placebo
11 Completed Monoclonal Antibody Therapy in Treating Patients With Leukemia
Conditions: Lymphoma;   Radiation Toxicity
Interventions: Drug: pentetic acid calcium;   Radiation: yttrium Y 90 daclizumab
12 Completed Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
Condition: Recurrent Small Cell Lung Cancer
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis
13 Completed Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: irinotecan hydrochloride;   Drug: thalidomide;   Other: pharmacological study
14 Completed Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers
Condition: No Evidence of Disease
Interventions: Drug: Celecoxib;   Other: Laboratory Biomarker Analysis;   Procedure: UV Light Therapy
15 Recruiting Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Vorinostat
16 Completed
Has Results
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx
Intervention: Drug: Akt inhibitor MK2206
17 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Gamma-Secretase Inhibitor RO4929097;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Procedure: Therapeutic Conventional Surgery
18 Not yet recruiting Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia
Interventions: Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
19 Completed Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: placebo;   Drug: Bowman-Birk inhibitor concentrate
20 Recruiting Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tamoxifen Citrate;   Drug: Z-Endoxifen Hydrochloride

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years